{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:27:59Z","timestamp":1761676079320},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.cjca.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T16:17:19Z","timestamp":1372954639000},"page":"1488-1494","source":"Crossref","is-referenced-by-count":15,"title":["Late and Very Late Stent Thrombosis in Patients With Second-Generation Drug-Eluting Stents"],"prefix":"10.1016","volume":"29","author":[{"given":"Ke Nan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia M.","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2013.04.001_bib1","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.108.813667","article-title":"Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents","volume":"119","author":"Eisenberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.04.001_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jacc.2011.06.049","article-title":"Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials","volume":"58","author":"Baber","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib4","unstructured":"Abbott Laboratories. Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy. Available at: http:\/\/www.abbott.com\/news-media\/press-releases\/abbotts-xience-prime-and-xience-v-drug-eluting-stents-receive-indication-in-europe-for-minimum-th.htm. Accessed August 28,\u00a02012."},{"key":"10.1016\/j.cjca.2013.04.001_bib5","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary stents","volume":"363","author":"Serruys","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2013.04.001_bib7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.03.005","article-title":"Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial","volume":"57","author":"Yeung","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacc.2009.08.067","article-title":"A\u00a0randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial","volume":"55","author":"Leon","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2010.03.086","volume":"56","author":"Park","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib11","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1253\/circj.CJ-10-0347","article-title":"Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) registry","volume":"74","author":"Hahn","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2013.04.001_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.108.803528","volume":"119","author":"Stone","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.jcin.2009.10.008","volume":"2","author":"Leon","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.04.001_bib14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(11)60395-4","article-title":"Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial","volume":"377","author":"Silber","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2013.04.001_bib15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ccd.22770","article-title":"Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial","volume":"77","author":"Garg","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.04.001_bib16","first-page":"E216","article-title":"Very late stent thrombosis and antineoplastic therapy","volume":"22","author":"Ghalchi","year":"2010","journal-title":"J\u00a0Invasive Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jacc.2011.03.013","article-title":"Second-generation drug-eluting stents. Moving the field forward","volume":"58","author":"Alfonso","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib18","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1161\/CIR.0b013e31823ba622","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/01.CIR.0000091115.05480.B0","article-title":"Pathological mechanisms of fatal late coronary stent thrombosis in humans","volume":"108","author":"Farb","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib20","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.693739","article-title":"Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization","volume":"115","author":"Finn","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2013.04.001_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcin.2010.02.008","article-title":"Optical coherence tomography assessment of in\u00a0vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents","volume":"3","author":"Guagliumi","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.04.001_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","article-title":"Endothelial cell recovery between comparator polymer-based drug-eluting stents","volume":"52","author":"Joner","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1253\/circj.CJ-08-0746","article-title":"Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography","volume":"73","author":"Katoh","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2013.04.001_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrcardio.2012.64","article-title":"The importance of the endothelium in atherothrombosis and coronary stenting","volume":"9","author":"Otsuka","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib25","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.jacc.2007.12.059","article-title":"Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion","volume":"51","author":"Hamilos","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCINTERVENTIONS.108.797928","article-title":"Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses","volume":"1","author":"Hamilos","year":"2008","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2013.04.001_bib27","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jacc.2009.01.051","article-title":"A\u00a0prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction","volume":"53","author":"Kim","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1755-5922.2010.00144.x","article-title":"Current status of drug-eluting stents","volume":"29","author":"Raber","year":"2011","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2013.04.001_bib29","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: the discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cjca.2013.04.001_bib30","doi-asserted-by":"crossref","first-page":"495S","DOI":"10.1016\/j.transproceed.2004.01.015","article-title":"The evolving experience using everolimus in clinical transplantation","volume":"36","author":"Formica","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cjca.2013.04.001_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/FJC.0b013e3180325b0a","article-title":"Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression","volume":"49","author":"Chen","year":"2007","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2013.04.001_bib32","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jacc.2005.11.092","article-title":"Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings","volume":"47","author":"Kotani","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2013.04.001_bib33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","article-title":"A\u00a0bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods","volume":"373","author":"Serruys","year":"2009","journal-title":"Lancet"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13002110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X13002110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T20:56:56Z","timestamp":1539550616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X13002110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0828282X13002110"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2013.04.001","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}